Evaluation of Hypervolemia in Children

Hypervolemia is a condition with an excess of total body water and when sodium (Na) intake exceeds output. It can have different causes, such as hypervolemic hyponatremia (often associated with decreased, effective circulating blood volume), hypervolemia associated with metabolic alkalosis, and end-stage renal disease. The degree of hypervolemia in critically ill children is a risk factor for mortality, regardless of disease severity. A child (under 18 years of age) with hypervolemia requires fluid removal and fluid restriction. Diuretics are able to increase or maintain urine output and thus improve fluid and nutrition management, but their benefit in preventing or treating acute kidney injury is questionable.

The Renal Effects of Traditional Nonsteroidal Anti-Inflammatory Agents Versus Cyclooxygenase-2 Inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for the management of acute and chronic pain as well as for rheumatoid arthritis and osteoarthritis. Although gastrointestinal complications are the most common adverse events associated with the use of these drugs, the renal adverse effects such as acute renal failure, electrolyte abnormalities, nephrotic syndrome, interstitial nephritis, and papillary necrosis can be serious. The cyclooxygenase-2 (COX-2)- selective NSAIDs (celecoxib, rofecoxib) have been associated with a reduced frequency of gastrointestinal adverse events, but questions still remain as to their renal safety. Recent information has suggested an increased role for COX-2 as a constitutive renal enzyme, thus implying its importance for normal kidney homeostasis. Clinical studies and published case reports of renal adverse events associated with COX-2 inhibitors suggest that patients with decreased effective circulating blood volume, salt depletion, and renal insufficiency have an increased likelihood of renal-related adverse events. Because many older patients have conditions that place them in one of the “at-risk” categories, this population should be monitored closely for the development of renal adverse events from any NSAIDs, including COX-2-selective agents.

SIADH: A Case Review

Because the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) can cause neurologic sequelae with the potential to affect long-term outcomes, its prompt recognition and treatment are essential. Normally, antidiuretic hormone (ADH) is secreted when effective circulating blood volume is decreased. SIADH is marked by secretion of ADH in the presence of effective or normal circulating blood volume. This causes plasma hyponatremia simultaneously with plasma hypo-osmolality and inappropriate hyperosmolality of the urine. This article explains the pathophysiology of the syndrome; describes its diagnosis, clinical course, and treatment; and exemplifies the syndrome with a case study.